drugset / Trial / NCT00017511

Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer

NCT00017511

Phase 3 Completed Daiichi Sankyo
Supportive care

Summary

RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of cevimeline in treating patients who have dryness of the mouth caused by radiation therapy for head and neck cancer.

Timeline

Start
2001-06
Primary completion
2003-03
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cevimeline Small molecule Oral